Cyclo Therapeutics, Inc.
CYTH · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $2 | $1 |
| % Growth | -21.8% | -13.2% | 75.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 90.9% | 89.9% | 90.2% | 92.7% |
| R&D Expenses | $14 | $9 | $9 | $6 |
| G&A Expenses | $6 | $8 | $6 | $4 |
| SG&A Expenses | $6 | $8 | $7 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $21 | $17 | $16 | $10 |
| Operating Income | -$20 | -$16 | -$14 | -$9 |
| % Margin | -1,862.7% | -1,134.8% | -899.8% | -991.8% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | -$20 | -$15 | -$14 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$20 | -$15 | -$14 | -$9 |
| % Margin | -1,863.4% | -1,110.7% | -902.1% | -987.7% |
| EPS | -1.23 | -1.81 | -2.25 | -5.58 |
| % Growth | 32% | 19.6% | 59.7% | – |
| EPS Diluted | -1.23 | -1.81 | -2.25 | -5.58 |
| Weighted Avg Shares Out | 16 | 8 | 6 | 2 |
| Weighted Avg Shares Out Dil | 16 | 8 | 6 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$20 | -$16 | -$14 | -$9 |
| % Margin | -1,860.9% | -1,134.1% | -899.9% | -990.6% |